Related Experiment Video
Updated: Aug 29, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Executive summary: Japanese guidelines for allergic conjunctival diseases 2021
Dai Miyazaki1, Atsuki Fukushima2, Eiichi Uchio3
1Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Tottori, Japan.
Allergic conjunctival disease (ACD) guidelines were updated in Japan in 2021. New treatments, including immunosuppressive eye drops, offer improved management for severe cases of allergic conjunctivitis and related conditions.
Area of Science:
- Ophthalmology
- Allergology
- Immunology
Background:
- Allergic conjunctival disease (ACD) encompasses several inflammatory eye conditions like allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
- These conditions stem from a type I hypersensitivity response to allergens, leading to significant ocular symptoms.
Purpose of the Study:
- To summarize the updated 2021 Japanese guidelines for allergic conjunctival diseases.
- To outline current diagnostic approaches, pathogenetic mechanisms, and therapeutic strategies for ACD.
- To evaluate the benefits and drawbacks of steroid and immunosuppressive treatments for severe ACD.
Main Methods:
- Review and synthesis of the third edition of the Japanese guidelines for allergic conjunctival diseases (2021).
- Assessment of clinical questions focusing on the use of steroids and immunosuppressive drugs in ACD treatment.
- Analysis of treatment protocols considering advantages and disadvantages.
Main Results:
- The introduction of immunosuppressive eye drops has notably altered treatment paradigms for severe ACD.
- The guidelines provide a framework for standardizing ACD treatment protocols.
- Comparative analysis highlights the roles and limitations of different therapeutic agents.
Conclusions:
- Updated guidelines offer enhanced strategies for managing allergic conjunctival diseases.
- Informed decision-making regarding ACD treatment is facilitated by understanding the efficacy and risks of various therapies.
- Healthcare providers and patients are empowered to actively participate in treatment planning for ACD.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Allergic Reactions
Angle Closure Glaucoma: Treatment
Allergic Drug Reactions
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

